Skip to content

Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics.

An Open-label Single-arm Study to Investigate Gastrointestinal Tolerance, Safety, and Acceptability of a New Infant Formula Containing Prebiotics, Probiotics and Postbiotics, in Healthy Term Infants.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04745455
Acronym
TREE
Enrollment
31
Registered
2021-02-09
Start date
2021-01-22
Completion date
2021-07-12
Last updated
2022-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Tolerance

Brief summary

A study to investigate the gastrointestinal tolerance and safety of a new formula containing prebiotics, probiotics and postbiotics.

Interventions

OTHERInfant formula containing prebiotics, probiotics and postbiotics

Infant formula containing prebiotics, probiotics and postbiotics

Sponsors

Nutricia Research
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Days to 84 Days
Healthy volunteers
Yes

Inclusion criteria

1. Term infants with a gestational age at birth of ≥37 weeks + 0 days and ≤41 weeks + 6 days; 2. Singleton, healthy infants as judged by the principle investigator; 3. Infants with age at screening ≥2 weeks (14 days) and ≤ 12 weeks (84 days) 4. Infants who are fully formula fed for at least 1 week prior to screening and whose parents have autonomously decided to fully formula feed, i.e. not to breastfeed or have ended breastfeeding, and who are intending to fully formula feed; 5. Written informed consent from the parent(s) and/or legally acceptable representative(s), aged ≥ 18 years.

Exclusion criteria

1. Infants who require to be fed a special diet other than standard cow's milk-based infant formula; 2. Infants known to have or suspected to have cow's milk protein allergy, lactose intolerance, or galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients; 3. Infants with known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters, such as but not limited to: GI malformations, congenital metabolic disorders, severe congenital cardiac disorders, immunodeficiency or major surgery, as per the clinical judgment of the Investigator; 4. Infants diagnosed with a gastrointestinal infection within 4 weeks prior to screening; 5. Infants with current or previous illnesses/conditions or interventions which could interfere with the study or its outcome parameters (e.g. diarrhea requiring treatment, constipation requiring treatment, regurgitation requiring treatment, dental/medical procedures which may impact oral feeding), as per the clinical judgment of the Investigator; 6. Received any of the following products/medication prior to screening: systemic antibiotics, prokinetics, proton pump inhibitors, prebiotic supplements, probiotic supplements, complementary feeding/weaning within 4 weeks prior to screening; 7. Incapability of infants' parents to comply with study protocol as per the judgment of the Investigator (e.g. fluency in local language, access to laptop/smartphone devices and internet connection required for data collection); 8. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products concomitantly or prior to study. \-

Design outcomes

Primary

MeasureTime frameDescription
Gastrointestinal toleranceBaselineA 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.

Secondary

MeasureTime frameDescription
Stool consistencyBaselineParent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard
Stool frequencyBaselineParent reported daily number of stools
Incidence, frequency, and severity of (S)AEs, and relatedness to study product of (Serious) Adverse Events.Through study completion, an average of one month(S)AE collection

Other

MeasureTime frameDescription
Well being questionnaireBaselineA parent reported 3-item questionnaire with individual scores from 1-5 (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree)
Study product appreciation questionnaire;Day 7A parent reported evaluation of product characteristics with a categorical rating scale and open questions

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026